News

Genentech and AC Immune partner again
Enlarge image

BusinessSwitzerland

Genentech and AC Immune partner again

19.06.2012 - Six years after their first alliance, Swiss AC Immune SA partners again with US-American Genentech Inc.

Basel/Lausanne – The subject of the new cooperation remained the same: fighting Alzheimer's disease. Therefore the Roche subsidiary has now in-licensed a second generation of AC Immune's antibodies - this time directed to bind the Tau protein. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and research, development and commercialisation milestone payments totalling more than CHF400m. Additionally, AC Immune could pocket royalties on net sales resulting from the collaboration – if the product is approved.

Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. The pharma will have global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of antibodies resulting from the collaboration. Scientifically, both partners are building on the first alliance as the new Tau antibodies are thought to flank Crenezumab, an antibody in phase II resulting from the first cooperation that binds amyloid-beta-plaques (abeta).

By blocking Tau- fibrillation and destroying abeta aggregates, AC Immune attacks the two crucial steps in Alzheimer development. AC Immune has raised CHF64m since its foundation in 2003. Financiers are business angels from Switzerland and prominent biotech supporters like Dietmar Hopp, the founder of the German business software maker SAP. Beside the out- licensed antibody projects, AC immune develops a proprietary small molecule pipeline

http://www.european-biotechnology-news.com/news/news/2012-02/genentech-and-ac-immune-partner-again.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 21.09.2014